Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death ligand-1 (PD-L1) (combined positive score [CPS]